The women who received valacyclovir also had half as many copies of HIV in their genital tracts compared to those who received the placebo, suggesting that valacyclovir has the potential to reduce the spread of HIV, Mayaud said.
"If the rate we saw in our study translates across sub-Saharan Africa, we're looking at more than 8,000,000 people in this region with HIV dementia," says Sacktor.
More than half of all new infections with the AIDS virus in Africa involve women and girls.
The trials' results were announced by their researchers last year.
The study is designed to test effectiveness.
